China Medical Technologies Inc.
China Medical Technologies Inc. (CMED) of Beijing, and Leica Biosystems, a division of Leica Microsystems of Wetzlar, Germany, will collaborate to develop and market fluorescence in situ hybridization (FISH) kits for the Leica Bond system, an automated staining platform. The companies will develop automated solutions for tissue sample tests on HER-2, EGFR and TOP2A genes, all of which play a role in targeted drug therapy for breast, lung and stomach cancer. They also will work on additional FISH applications. CMED will sell the kits in China, while Leica will have the option to sell them in the rest of the world.